NUVB

3.8000.26%
DT

David T. Hung

Founder, President, CEO & Chairman

Dr. David T. Hung, M.D., serves as Founder, President, Chief Executive Officer and Director at Nuvation Bio Inc since April 2018 and has been it's Chairman of the Board since September 03, 2024. He founded Medivation, Inc in 2003 and served as its President, Chief Executive Officer and Director until 2016. He served as Chief Financial Officer at Nuvation Bio, Inc. until 2020. He served as Chief Scientific Officer from 1998 to 1999 at ProDuct Health, In and served as its president and Chief Executive Officer from 1999 to 2001 until its acquisition by Cytyc Corporation. He served as Scientific Advisor of Group at Sio Gene Therapies, Inc. (formerly known as Axovant Sciences Ltd.) since April 7, 2017. He has many leadership and management experience in the life sciences industry. Dr. Hung served as the Chief Executive Officer and Director of Axovant Sciences Ltd. since April 7, 2017 until February 12, 2018. He served as its Chief Executive Officer and President since December 17, 2004 until September 28, 2016. Dr. Hung served as the Chief Executive Officer and President of Medivation Neurology, Inc since September 2003 until December 2004. He co-founded Medivation in 2003. He served as Consultant and Adviser of Freedom Eye Ltd. since July 13, 2006. From 1998 to 2001, he was employed by Pro-Duct Health Inc. where he served as its Chief Scientific Officer from 1998 to 1999 and President and Chief Executive Officer from July 1999 to November 2001. He served as the Chief Executive Officer and President of Orion Acquisition Corp. II since Decefmber 17, 2004. Dr. Hung is a specialist medical expertise is in internal medicine and oncology. From 1995-1998, he served in various senior positions at Chiron Corporation, a public biotechnology company, with his last position being Vice President of Preclinical Research, Vice President of Lead Discovery and Development and Vice President of New Projects. He served as a Consultant to Cytyc Corporation from December 2001 to January 2003. Dr. Hung has extensive industry experience in the development and commercialization of cancer therapies. He has experience in molecular biology research, having completed basic research fellowships at the Brain Tumor Research Institute and the Cardiovascular Research Institute and heading a National Institute of Health-funded laboratory at the University of California San Francisco. He has been an Independent Director of NovoCure Ltd since May 31, 2018. He served as a Director of Agilvax, Inc. since January 9, 2019. He served as Director of Establishment Labs Holdings Inc. since February 2016 until February 11, 2021. He served as a Director of Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies Ltd.). since April 7, 2017 until February 12, 2018. He serves as Director of NKT Therapeutics Inc. He served as an Executive Director of Medivaton Inc. since December 17, 2004 until September 28, 2016. He served as a Director of Medivation Neurology, Inc. since September 2003 until December 2004. He served as an Independent Director of Opexa Therapeutics, Inc. since May 16, 2006 to October 27, 2011. He served as a Director of Sportan United Industries Inc. since May 15, 2006. He served as a Non-Executive Director of FYI Resources Limited from October 2004 to July 13, 2006. He served as a Director of LifeSync Holdings Inc. since July 1999; and Orion Acquisition Corp. II since December 17, 2004. He is a Hematologist, Oncologist and Molecular Biologist. He is an internationally recognized physician with expertise in internal Medicine and Oncology. He received his M.D. from the University of California at San Francisco, School of Medicine and his M.A. and A.B. in Biology and Organic Chemistry from Harvard College. Dr. Hung served as Director of ARYA Sciences Acquisition Corp since 2018.

Positions